Cover Image
QR Code

Crohn's disease presenting with pyoderma gangrenosum and treated with infliximab.

Pyoderma gangrenosum is one of the more uncommon extraintestinal manifestations of Crohn's disease and, more broadly, inflammatory bowel disease. Little is known regarding the pathophysiology of pyoderma gangrenosum. However, treatment of systemic inflammatory disorders (eg, rheumatoid arthritis) an...

Full description

Published in:Hospital Physician Vol. 40; no. 11; pp. 43 - 48
Main Authors: Papper MA, Chen WT, Akerman PA
Format: case study pictorial tables/charts Journal Article
Published: Turner White Communications 2004 Nov
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106649361&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106649361
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        0888241X
        6AZ
      jtl: Hospital Physician
      issn: 0888241X
      maglogo: N
    pubinfo:
      dt: 2004 Nov
      vid: 40
      iid: 11
      pid: 14051
      pub: Turner White Communications
      place: Wayne, Pennsylvania
    artinfo:
      ui:
        106649361
        106649361
        2005097293
        106649361
      ppf: 43
      ppct: 5
      formats:
      tig:
        atl: Crohn's disease presenting with pyoderma gangrenosum and treated with infliximab.
      aug:
        au:
          Papper MA
          Chen WT
          Akerman PA
        affil: Gastroenterology Fellow, Robert Wood Johnson School of Medicine, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ
      sug:
        subj:
          Crohn Disease Diagnosis
          Infliximab Therapeutic Use
          Pyoderma
          Adult
          Diagnosis, Laboratory
          Male
          Reference Values
          Adult: 19-44 years
          Male
      ab: Pyoderma gangrenosum is one of the more uncommon extraintestinal manifestations of Crohn's disease and, more broadly, inflammatory bowel disease. Little is known regarding the pathophysiology of pyoderma gangrenosum. However, treatment of systemic inflammatory disorders (eg, rheumatoid arthritis) and dermatologic disorders (eg, psoriasis) with tumor necrosis factor-alpha (TNF-alpha) inhibitors has had promising results; TNF-alpha inhibitors may help to elucidate a clearer connection between Crohn's disease and pyoderma gangrenosum. We report a case of a 29 -year-old man with pyoderma gangrenosum associated with Crohn's disease. Following treatment with infliximab, his Crohn's disease as well as his cutaneous ulcers improved markedly. We suggest that TNF-alpha suppression, in addition to its possible efficacy in treating fistulizing Crohn's disease, might prove beneficial in alleviating cutaneous symptoms by a similar mechanism.
      pubtype: Periodical
      doctype:
        case study
        pictorial
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N